Using Pain Quality Assessment Measures for Selecting Analgesic Agents

Although those in the field of pain management have long recognized the multidimensional character of pain, global pain intensity remains the most frequently assessed domain measured in clinical trials of pain treatments. However, a number of specific pain qualities have been shown to be associated with neuropathic versus nociceptive pain and, as such, can be used for diagnostic purposes. In addition, preliminary evidence suggests that pain quality measures may be helpful for measuring outcomes in clinical trials. A number of such measures are currently available, each with its strengths and weaknesses. These measures are reviewed, and potential future uses of these tools are discussed.

[1]  H. Ugurlu,et al.  Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury , 2004, Spine.

[2]  W. Clark,et al.  Preoperative Multidimensional Affect and Pain Survey (MAPS) scores predict postcolectomy analgesia requirement. , 2000, The Clinical journal of pain.

[3]  B. Galer,et al.  Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. , 2005, The journal of pain : official journal of the American Pain Society.

[4]  B. Galer,et al.  Development and preliminary validation of a pain measure specific to neuropathic pain , 1997, Neurology.

[5]  P. Salovey,et al.  The McGill pain questionnaire reconsidered: Confirming the factor structure and examining appropriate uses , 1985, Pain.

[6]  I. Higginson,et al.  Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds Assessment of Neuropathic Symptoms and Signs Scale. , 2003, Journal of the Royal Society of Medicine.

[7]  M. Bennett,et al.  The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs , 2001, Pain.

[8]  Lars Arendt-Nielsen,et al.  Comparative EEG activation to skin pain and muscle pain induced by capsaicin injection. , 2004, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[9]  Elif Kocasoy Orhan,et al.  Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. , 2004, The journal of pain : official journal of the American Pain Society.

[10]  Blair H. Smith,et al.  The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. , 2005, The journal of pain : official journal of the American Pain Society.

[11]  Bernard Laurent,et al.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) , 2005, Pain.

[12]  Misha-Miroslav Backonja,et al.  Development of a Neuropathic Pain Questionnaire , 2003, The Clinical journal of pain.

[13]  S. Sherman,et al.  Effectiveness of tizanidine in neuropathic pain: an open-label study. , 2000, The journal of pain : official journal of the American Pain Society.

[14]  Ronald Melzack,et al.  The McGill Pain Questionnaire: Appraisal and current status. , 2001 .

[15]  Ronald Melzack,et al.  The short-form McGill pain questionnaire , 1987, Pain.

[16]  Misha-Miroslav Backonja,et al.  Neuropathic Pain Questionnaire—Short Form , 2003, The Clinical journal of pain.

[17]  R. Melzack.  The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.

[18]  Jacques Fermanian,et al.  Development and validation of the Neuropathic Pain Symptom Inventory , 2004, Pain.